About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Dengue Fever Vaccine Less Effective

by Sheela Philomena on September 11, 2012 at 9:57 AM
Font : A-A+

 Dengue Fever Vaccine Less Effective

A new vaccine against dengue falls short of its goal, the vaccine failed to protect against all its viral strains, report researchers.

Tested among just over 4,000 children in rural Thailand who were badly exposed to the mosquito-borne fever, the vaccine had no side effects but only worked against three out of the four dengue strains.

Advertisement

The outcome shows that the quest is far from over, but the good news is "a safe vaccine against dengue is possible", the researchers said in The Lancet.

According to the UN's World Health Organisation (WHO), between 50 and 100 million dengue infections occur each year in more than 100 countries. In 1970, the disease was endemic in just nine countries.
Advertisement

Half a million people each year develop severe dengue, a feverish condition requiring hospitalisation.

But the search for the vaccine has been complicated by the fact that there are four different strains -- known as DENV 1, 2, 3 and 4 -- all of which may circulate in an outbreak zone.

Adding to the problem is that dengue seems to be exclusive to humans, which means it is impossible to test vaccines on lab animals first.

As a result, trials have to proceed with even greater caution than usual, and the formula has to be built up incrementally, on what has previously been tested.

The candidate vaccine, CYD-TPV, was given to 2,669 children in three doses, while 1,333 were given a harmless lookalike called a placebo to act as a comparison.

The trial was a so-called Phase IIb, meaning a stepped-up test in the long three-phase process by which new drugs are tested for safety and effectiveness.

In the vaccine group, 76 children, or 2.8 percent, fell diagnosed with dengue, compared with 58 cases, or 4.4 percent, among the control group.

But among the inoculated children, protection against DENV 1, 3, 4 was 55.6 percent, 75.3 percent and 100 percent -- but against DENV 2, it was just 9.2 percent. Overall, the protection was just 30.2 percent.

French pharmaceutical giant Sanofi Pasteur said that despite this disappointment, the story was not yet over.

Phase III trials of CYD-TPV are underway in several other countries, where different conditions may give a different outcome or, possibly, tips for a solution to widen the vaccine's shield.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
COVID Toes
International Yoga Day 2022 - 'Yoga for Humanity'
Wearable Devices Are Now Transforming Depression, Multiple Sclerosis, and Epilepsy Management.
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Dengue Fever Dengue / Dengue Hemorrhagic Fever Mosquito Diseases Dengue and Homeopathy Chikungunya and Homeopathy Febrile Fits / Febrile Convulsions Chikungunya Dengue Q Fever Vaccination for Children 

Most Popular on Medindia

Noscaphene (Noscapine) Nutam (400mg) (Piracetam) Find a Hospital Daily Calorie Requirements Drug - Food Interactions Selfie Addiction Calculator Hearing Loss Calculator Color Blindness Calculator Accident and Trauma Care Iron Intake Calculator

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE